Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

Autor: Ole S. Nielsen, Per Dombernowsky, Henning Mouridsen, Søren Daugaard, Martine Van Glabbeke, Anne Kirkpatrick, Jaap Verweij

Publikováno v: Sarcoma, Vol 4, Iss 1-2, Pp 31-35 (2000)

Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have sug

Externí odkaz: https://doaj.org/article/877a787ac2b44e61b19b98367642c66c

A Retrospective Clinicopathological Study of 37 Patients With Chordoma: A Danish National Series

Autor: Akmal Safwat, Ole S. Nielsen, Anne G. Jurik, Johnny Keller, Ernst R. Weeth, Bjarne Lund, Olaf Myhre-Jensen

Publikováno v: Sarcoma, Vol 1, Iss 3-4, Pp 161-165 (1997)

Purpose. There are, in general, few published series on chordoma. It is a rare disease and further data are still needed.

Externí odkaz: https://doaj.org/article/78377a849221414d9c9600cbb6281e5f

Role of systemic treatment in adult soft tissue sarcomas

Autor: Ole S. Nielsen

Publikováno v: European Journal of Cancer Supplements. 1:249-259

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::62e2cebc665078ef8dd2fd44abc9ee3d
https://doi.org/10.1016/s1359-6349(03)90029-2

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

Autor: L. Svancarova, Jaap Verweij, Ian Judson, P Dombernowsky, Cédric Hermans, A. van Oosterom, D. Spooner, Krzysztof Krzemieniecki, Henning T. Mouridsen, M. van Glabbeke, Ole S. Nielsen

Publikováno v: van Oosterom, A T, Mouridsen, H T, Nielsen, O S, Dombernowsky, P, Krzemieniecki, K, Judson, I, Svancarova, L, Spooner, D, Hermans, C, Van Glabbeke, M & Verweij, J 2002, ' Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients ', European Journal of Cancer, vol. 38, no. 18, pp. 2397-406 . https://doi.org/10.1016/S0959-8049(02)00491-4
European Journal of Cancer, 38, 2397-2406. Elsevier Ltd.

The aim of this phase 11 study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy. Two different schedules of ifosfamide were investigated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cfae226d4b530bff02663fe87615d3b
https://doi.org/10.1016/s0959-8049(02)00491-4

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcoma

Autor: Ian Judson, Ole S. Nielsen, M. van Glabbeke, Jaap Verweij

Publikováno v: Van Glabbeke, M, Verweij, J, Judson, I & Nielsen, O S 2002, ' Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas ', European Journal of Cancer, vol. 38, no. 4, pp. 543-9 . https://doi.org/10.1016/S0959-8049(01)00398-7
van Glabbeke, M, Verweij, J, Judson, I & Nielsen, O S 2002, ' Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma ', European Journal of Cancer, vol. 38, no. 4, pp. 543-549 . https://doi.org/10.1016/S0959-8049(01)00398-7
European Journal of Cancer, 38, 543-549. Elsevier Ltd.

We have estimated progression-free rates (PFR) for various groups of soft-tissue sarcoma patients from our clinical trials database, to provide reference values for conducting phase II studies with PFR as the principal end-point. In 146 pretreated pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f16027dc734baebd6fc929a5ea37a9
https://doi.org/10.1016/s0959-8049(01)00398-7